.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advanced Ovarian Cancer: New Perspectives on Systemic Therapy

EP. 1: Frontline Treatments in Ovarian Cancer

October 24th 2019

EP. 2: Predictive Biomarkers in Ovarian Cancer

October 24th 2019

EP. 3: Somatic Testing in Ovarian Cancer

October 24th 2019

EP. 4: The Importance of HRD Testing in Ovarian Cancer

October 24th 2019

EP. 5: Combination Veliparib and Chemotherapy in Ovarian Cancer

October 24th 2019

EP. 6: PARP Inhibition in BRCA1/2+ or HRD- Ovarian Cancer

October 24th 2019

EP. 7: Adverse-Effect Profiles of PARP Inhibitors in Ovarian Cancer

October 24th 2019

EP. 8: PARP Inhibitors and Indications in Ovarian Cancer

October 24th 2019

EP. 9: Maintenance Therapy in Ovarian Cancer

October 24th 2019

EP. 10: Treatment of Emergent Adverse Events in Ovarian Cancer

October 24th 2019

EP. 11: Treatment of HRD-Negative Ovarian Cancer

October 24th 2019

EP. 12: New Options for Recurrent Ovarian Cancer

October 24th 2019

EP. 13: Low-Grade Serous Ovarian Cancer

October 24th 2019

EP. 14: Paradigms of Success in Ovarian Cancer

October 24th 2019